Quadria Capital Invests Rs 850 Cr In NephroPlus
The demand for dialysis services in NephroPlus's target markets is projected to grow at a rate of over 11 per cent annually over the next five years.
Quadria Capital, a healthcare-focused private equity firm in Asia, has announced a significant investment of Rs 850 Crores in NephroPlus, the largest dialysis network in Asia, the former informed in a press statement on Monday. This investment marks the largest ever in India's nephrology sector, the statement read.
Through this transaction, Quadria will acquire a substantial minority stake in NephroPlus, combining a primary investment with the purchase of shares from existing shareholders. The infusion of capital will enable NephroPlus to expand its network of dialysis centres across India and other Asian markets, addressing the growing demand for high-quality and affordable dialysis services.
NephroPlus collaborates with renowned nephrologists and operates dialysis centres within prestigious hospitals alongwith standalone clinics. Additionally, NephroPlus engages in public-private partnerships to deliver dialysis care in urban and rural areas.
The demand for dialysis services in NephroPlus's target markets is projected to grow at a rate of over 11 per cent annually over the next five years.
Vikram Vuppala, Founder and CEO of NephroPlus, expressed his enthusiasm for the partnership with Quadria, highlighting the company's commitment to expanding its presence in India while exploring opportunities in other global markets. He s NephroPlus's dedication to delivering affordable and high-quality care to its patients, leveraging Quadria's healthcare expertise and capital to fuel further growth and innovation.
Sunil Thakur, Partner and Head of South Asia at Quadria Capital, highlighted the firm's focus on investing in regional healthcare champions like NephroPlus, which play a crucial role in addressing the healthcare needs of underserved populations. Thakur highlighted NephroPlus's track record of improving health outcomes for patients and expressed confidence in the company's potential for continued growth with Quadria's support.
